The global Antibody Drug Conjugates Market in terms of revenue was estimated to be worth $9.7 billion in 2023 and is poised to reach $19.8 billion by 2028, growing at a CAGR of 15.2% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Growth in the market can be attributed to various factors such as including the growing prevalence of cancer and increasing R&D activities for the development of novel ADCs by key market players. Antibody-drug conjugates represent a highly potent approach to treating cancer patients. They harness the precision of monoclonal antibodies, directing them towards specific antigens, to deliver potent cytotoxic drugs. This approach enhances drug effectiveness while minimizing the adverse effects typically associated with traditional chemotherapy.

Key players in the antibody drug conjugates market include F. Hoffmann-La Roche Ltd (Switzerland), Daiichi Sankyo Company, Limited (Japan), Seagen Inc. (US), Gilead Sciences, Inc. (US), Takeda Pharmaceutical Company Limited (Japan), Pfizer Inc. (US), Astellas Pharma Inc (Japan), AstraZeneca (UK), ADC Therapeutics SA (Switzerland), ImmunoGen, Inc. (US), Zydus Group (India).

Download a FREE Sample PDF of the Global Antibody Drug Conjugates Market Research Report at https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=122857391&utm_source=Ganesh&utm_medium=P

This report categorizes the antibody drug conjugates market to forecast revenue and analyze trends in each of the following submarkets:

By Product

• Kadcyla
• Enhertu
• Adcetris
• Padcev
• Trodelvy
• Polivy
• Others

By Disease Type

• Breast Cancer
• Blood Cancer
• Others

By Linker Type

• Non-Cleavable
• Cleavable

By Target

• HER2
• CD22
• CD30
• Others

By Payload Type

• MMAE/auristatin
• calicheamicin
• Maytansinoids
• Others

By Region

• North America
• US
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Rest of Asia Pacific
• Latin America
• Brazil
• Rest of Latin America
• Middle East & Africa

The Kadcyla segment of the antibody drug conjugates industry held the dominant position in 2022.

On the basis of product, the global antibody drug conjugates market is segmented into Kadcyla, Enhertu, Adcetris, Padcev, Trodelvy, Polivy and Others. The Kadcyla segment dominated the antibody drug conjugate market during the forecast period. The rising prevalence of breast cancer coupled with increased approvals for the ADCs for breast cancer treatment are some of the factors driving the market growth.

Blood Cancer Segment of the antibody drug conjugates is likely to grow at significant CAGR during the forecast period.

On the basis of disease type, the global antibody drug conjugates market is segmented into breast cancer, blood cancer and others. The breast cancer segment dominated the market in 2022 owing to various factors such as increased adoption of ADCs for treatment by patient population. The increasing number of clinical trials on ADCs for breast cancer and the recent approvals of ADCs target indications, such as blood cancer, lung cancer, cervical cancer, and ovarian cancer among others is further expected to project the market growth at faster pace.

Direct Purchase of the Global Antibody Drug Conjugates Market Research Report at https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=122857391&utm_source=Ganesh&utm_medium=P

Asia Pacific region of the antibody drug conjugates industry is likely to grow at the highest CAGR during the forecast period of 2023-2028.

The antibody drug conjugates market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America accounted for the largest share of the market, and this trend is expected to continue during the forecast period. A robust product pipeline and increased regulatory approvals of ADCs are likely to propel the market growth in the region.  Asia Pacific segment is likely to grow at a higher CAGR owing to various factors such as the increasing number of cancer cases coupled with the rise in the use of ADCs for the treatment of cancer. Furthermore, the launch of biosimilar Ujivra by Zydus is likely to have a positive impact on the market growth in the coming years.